Dry mouth (xerostomia) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review
Johansson 2001 (crossover, n=33, Sjogren's syndrome): both products improved oral dryness and chewing/swallowing; Salinum alone reduced speaking problems and burning mouth. Paired data not accounted for; no usable…
1 study · 33 participants
GRADE not reported
Salivary flow / oral health · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review
No difference between device and bolus in unstimulated whole saliva, oral microbial profile or generalised inflammation.
1 study · 22 participants
GRADE not reported
Improvement in dry mouth (dichotomous) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
Mucin spray (Saliva Orthana) led to lower improvement in dry mouth (dichotomous) compared with placebo spray (base without mucin); GRADE not reported.
1 finding from 1 review
Sweeney 1997 (parallel, n=31, terminal cancer): both sprays improved dry mouth symptoms but no statistically significant difference between mucin spray and placebo for improved dry mouth (Analysis 1.1; RR not…
1 study · 31 participants
GRADE not reported
Dry mouth (xerostomia) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
Biotene Oral Balance mouthcare system led to higher xerostomia (VAS mouth dryness) compared with bioxtra mouthcare system; GRADE not reported.
1 finding from 1 review
Unstimulated whole saliva (UWS) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review
Aagaard 1992 (crossover, n=43): approximately 50% of participants had an increase in unstimulated whole saliva from all products; unclear how many completed the trial; no usable data.
1 study · 43 participants
GRADE not reported
Patient preference · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review
Patient preference · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review
Amount of analgesia · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
None of the prophylactic aciclovir versus placebo trials reported on amount of analgesia. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
0 studies
No studies found
Patient quality of life · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
None of the prophylactic aciclovir versus placebo trials reported on patient quality of life. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
0 studies
No studies found
Presence/absence of HSV oral lesions · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)
Prophylactic valaciclovir (lower dose) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (higher dose); GRADE not reported.
1 finding from 1 review
Viral isolates (HSV isolates identified, with or without clinical symptoms) · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) led to lower viral isolates (HSV isolates identified, with or without clinical… compared with placebo; GRADE not reported.
1 finding from 1 review
Viral isolates · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)
1 finding from 1 review
Orlowski 2004: 182 throat swabs performed for patients receiving 500 mg of valaciclovir (n = 40) and 198 swabs for those receiving 1000 mg (n = 41); all of the cultures proved negative (1 trial, 81; not estimable).
1 study · 81 participants
GRADE not reported
Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (oral); GRADE not reported.
1 finding from 1 review
Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) led to lower presence/absence of HSV oral lesions compared with placebo; GRADE not reported.
1 finding from 1 review
Length of hospital stay · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Recurrence of lesions · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)
1 finding from 1 review
One study reported adverse effects (Warkentin 2002). Twenty patients allocated to receive high dose valaciclovir reported adverse effects (42%); for the low dose group this number was 27 (52%). Adverse effects were…
1 study · 100 participants
GRADE not reported
Cost of oral care · Patients being treated for cancer (predominantly haematological malignancies)
1 finding from 1 review
Only one trial reported on the cost of prophylaxis for HSV (Liesveld 2002). The reported mean pharmacy costs for those randomised to receive aciclovir were $1080 compared to $320 for those initially randomised to…
1 study · 30 participants
GRADE not reported
Viral isolates · Patients being treated for cancer (leukaemia)
Prophylactic prostaglandin E (oral) led to higher viral isolates compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse effects · Patients being treated for cancer (predominantly haematological malignancies)
1 finding from 1 review